Currently, primary tumor stage, serum PSA level, and biopsy Gleason grade are utilized during clinical assessment to predict the pathologic stage of the tumor and the treatment efficiency, however, none or even a combination of these indicators are sufficient to reliably anticipate outcome for patients [3], [4]. This evidence concerns the gene KLK3 and neoplasm.